



This is an open access article distributed in accordance with the Creative Commons Attribution (CC BY 4.0) license: <https://creativecommons.org/licenses/by/4.0/> which permits any use, Share — copy and redistribute the material in any medium or format, Adapt — remix, transform, and build upon the material for any purpose, as long as the authors and the original source are properly cited. © The Author(s) 2021

# Clinical and laboratory characteristics of COVID-19 infection in patients presenting to a tertiary care hospital

Huma Batool<sup>1\*</sup>, Asifa Karamat<sup>2</sup>, Khalid Waheed<sup>3</sup>, Sohail Anwar<sup>4</sup>, Syed Arslan Haider<sup>5</sup>, Syed Mazhar Ali Naqvi<sup>6</sup>, Munaza Javed<sup>7</sup>

## ABSTRACT

**Background and Objective:** COVID-19 disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) having a wide variety of clinical features ranging from asymptomatic carriers to respiratory failure requiring mechanical ventilation. The objective of the study was to analyze the spectrum of different symptoms, laboratory findings, and complications in patients who were admitted in either COVID ward or intensive care unit (ICU) of a local hospital.

**Methods:** A retrospective cohort study of the medical records of 100 COVID-19 disease patients with polymerase chain reaction (PCR) detected SARS-CoV-2 infection were collected. Participant information was retrospectively obtained from the hospital medical records which included clinical records and laboratory findings. All statistical analyses were done using Statistical Package for the Social Sciences version 21.

**Results:** The mean age of the patients was  $50.8 \pm 5.86$  with male predominance (79%). Most frequent co-morbidities were diabetes mellitus (42%) and hypertension (36%). Most frequent symptoms were fever (95.9%) and fatigue (95.9%) followed by dry cough (86.5%), myalgia (85.1), and shortness of breath (70%). Amongst the patients admitted, leukocyte count was  $10.95 \times 10^3$ , C-reactive protein was 12.8 mg/dl, ferritin was 730.8 ng/ml, and lactate dehydrogenase was found to be 1,254.7 U/l. Hepatic and renal functions were borderline deranged.

**Conclusion:** COVID-19 disease has a wide spectrum of clinical symptoms. Patients with raised inflammatory markers have severe disease and are more likely in need of an ICU care. By carefully observing these markers may help in better management of COVID-19 disease.

**Keywords:** Coronavirus, intensive care unit, COVID-19, complications, laboratory markers.

**Received:** 11 August 2021

**Revised date:** 03 September 2021

**Accepted:** 11 September 2021

**Correspondence to:** Huma Batool

\*Assistant Professor of Pulmonology, Lahore General Hospital, Lahore, Pakistan.

**Email:** humabatool3@gmail.com

Full list of author information is available at the end of the article.

## Introduction

COVID-19 disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is highly communicable virus. The first case was reported in China by the end of December 2019 and till July 2020 more than ten million cases were reported worldwide.<sup>1</sup> A rapid surge in cases has led to the collapse of health-care systems in several countries. There is day-by-day increase in cases in Pakistan also. Therefore, the understanding of the clinical spectrum of the disease, laboratory findings and their association with disease severity is very crucial in triage and efficient management of the patients.

Novel coronavirus disease (COVID-19) has a variety of clinical features ranging from asymptomatic carriers of

the disease to respiratory failure requiring mechanical ventilation.<sup>2</sup> According to the literature available, number of patients who need intensive care unit (ICU) care cannot be certain but 6.1% are classified as critical (multi-organ failure, needing mechanical ventilation), while 13.8% as severe (oxygen saturation less than 90% on room air requiring oxygen). Worldwide data shows that mostly affected individuals belong to old age ranging from 65-85 years.<sup>3</sup> China, the first hit country by novel coronavirus, reports age range from 10 to 80 years.<sup>4</sup> Clinically, novel coronavirus disease has a wide range of clinical and laboratory parameters. The most common feature is fever (98.6%) followed by fatigue, cough, muscular pain, dyspnea, and less frequently headache,

dizziness, abdominal pain, diarrhea, nausea, and vomiting.<sup>1,5</sup> Coronavirus more commonly infects people with different comorbidities including hypertension (HTN), diabetes, cardiovascular and cerebrovascular disorders.<sup>6-9</sup>

As currently there is no definitive treatment available for novel coronavirus disease, association of laboratory parameters with severity and potential need of intensive care is quite important. Fan et al.<sup>10</sup> analyzed that hematological index relates to severity of disease in COVID-19-infected patients. Common hematological abnormalities are lymphocytopenia, thrombocytopenia, leukopenia, and high C-reactive protein (CRP) levels.<sup>2,11</sup> Liver enzyme derangement is also expected, though data is limited, as was seen in SARS and middle east respiratory syndrome.<sup>12,13</sup>

The authors studied the clinical as well as laboratory parameters of SARS-CoV-2 which helps in understanding the characteristics of this emerging disease. Moreover, with careful observation of clinical and laboratory parameters, the future requirement of ICU admission in these patients can be ascertained.

## Methods

It was a retrospective study of the medical records of 100 COVID-19 disease patients with PCR proven SARS-CoV-2 infections who were admitted in isolation wards and ICU of Lahore General Hospital, Lahore, Pakistan. Diagnosis was made through RT-PCR of the nasal swabs of all patients. The study was approved by Ethical Review Committee of Post Graduate Medical Institute/Ameer-ud-Din Medical College Lahore General Hospital Lahore (Reference No. 00-125-20, Dated: 20-07-2020). The duration of this study was 3 months from August 2020 to September 2020. Patients who were  $\geq 18$  years with RT-PCR positive for SARS-CoV-2 were included in this study, whereas patients with missing data and having negative real time polymerase chain reaction (RT-PCR) were excluded.

Patient information was retrospectively obtained from the hospital medical records. Detailed clinical history and physical examination were done on the day of admission, and complete blood counts, liver function tests, renal function tests, CRP, lactate dehydrogenase (LDH), serum ferritin, and serum electrolytes were performed within the 48 hours following admission.

## Statistical analysis

Statistical Package for Social Sciences version 21 was used in this study. Descriptive statistics like mean, standard deviation, frequency, and percentages were collected for demographics and clinical characteristics. Independent *t*-test was used to find out the differences between patients in ward and ICU with different laboratory test reports.

## Results

The mean age of the patients enrolled was  $50.8 \pm 5.86$  SD with 79% male and 21% female. Eighty-eight percent of the population belonged to urban area, while the rest (12%) were from rural areas. Majority (65%) were nonsmokers. Most frequent comorbidities were diabetes mellitus (42%) and HTN (36%). Most frequent symptom was fever (95.9%) and fatigue (95.9%) followed by dry cough (86.5%), myalgia (85.1%), and shortness of breath (70%).

Mean saturation of the patients on presentation was  $89.7 \pm 5.59$ . Mean leucocyte count was  $10.95 \pm 5.10$ , predominantly including neutrophils (67.8%) followed by lymphocyte (14.4%). Among inflammatory markers, mean CRP was  $12.8 \pm 5.70$ , serum ferritin  $730.8 \pm 3.27$ , and LDH  $1,254.7 \pm 3.47$ . D-Dimers were markedly raised (13.8 mg/l). Bilirubin levels were 0.98 mg/dl while liver enzymes were slightly raised [alanine aminotransferase (ALT) = 71.8 U/l, aspartate aminotransferase (AST) = 76.8 U/l]. Initial serum creatinine and urea was nearly normal in the study population although quite a few ( $n = 23$ ) developed renal involvement later on during the disease course (Table 1).

More than half (68%) of patients recovered, while 12% patients expired; however the rest of 20% were hospitalized at the time of data collection.

Independent *t*-test was used to find out the differences of COVID-19 patients who were admitted in ward and ICU with different laboratory tests findings. According to the findings, significant differences were observed in SPO<sub>2</sub>, WBCs, Hb, lymphocytes, platelets, CRP, ferritin, and D-dimers between patients in ward and ICU. It was seen that patients who were admitted in ICU showed higher levels of WBCs, CRP, ferritin, and D-dimer levels as compared to patients in the wards. It was also noted that patients admitted in the ward had more SPO<sub>2</sub>, Hb, lymphocytes, and platelets as compared to ICU patients. Moreover, no significant differences were found between the patients admitted in wards and ICU with reference to creatinine, bilirubin, urea, AST, ALT, sodium, potassium, LDH, and neutrophil counts (Table 2).

## Discussion

Male gender, old age, and comorbidities including active cancer, coronary artery disease, liver and kidney dysfunctions, chronic obstructive pulmonary disease, diabetes, and hypercholesterolemia are the factors associated with mortality among patients with COVID-19 who were admitted to ICU.<sup>14,15</sup> The knowledge of common clinical features and laboratory characteristics can help in accurately predicting the presence of infection and severity of disease in patients with COVID-19 infection. In the previous viral epidemics, old age was a prime predictor of mortality.<sup>16,17</sup> The mean age reported in the present study coincides with most of the other

**Table 1.** Demographic, clinical characteristics, and complications during course of disease of studied sample (N = 100).

Variables	Frequency (n)	Percentage
<b>Demographic characteristics</b>		
Age (mean)	50.8 ± 5.86 S.D.	
Gender (%)		
Male	79	79
Female	21	21
Area		
Urban	88	88
Rural	12	12
Smoking status		
Non smoker	65	65
Smoker	35	35
<b>Comorbidities</b>		
Diabetes mellitus	42	42
HTN	36	36
Ischemic heart disease (IHD)	7	7
Malignancy	1	1
Stroke	1	1
Asthma	1	1
Active tuberculosis	1	1
Hypothyroidism	1	1
<b>Complications</b>		
Pneumonia	76	76
Respiratory failure	68	68
Acute respiratory distress syndrome (ARDS)	30	30
Septic shock	9	9
Acute kidney injury (AKI)	23	23
Disseminated intravascular coagulation	11	11
<b>Laboratory characteristics</b>		
	<b>Mean (M)</b>	<b>Standard deviation (SD)</b>
Oxygen saturation (SpO2)	89.76	±5.59
White blood cell count (WBC) ×10 <sup>3</sup> (μ/l)	10.95	±5.10
Hemoglobin (Hb) (g/dl)		
Neutrophils	12.43	±1.67
Lymphocytes	67.79	±4.77
Platelets (μ/l)	14.35	±3.27
LDH (U/l)	267,287.67	±5.43
CRP (mg/dl)	1,254.71	±3.47
Ferritin (ng/ml)	12.83	±5.70
Bilirubin (mg/dl)	730.83	±3.27
AST (U/l)	0.98	±0.72
Alanine amino transferase (U/l)	76.81	±6.10
Urea (mg/dl)	71.86	±2.20
Creatinine (mg/dl)	55.88	±4.27
D-Dimers (mg/l)	1.19	±0.44
Sodium (mEq/l)	13.8	±1.25
Potassium (mEq/l)	137.58	±3.88
	4.12	±0.48

studies.<sup>5,6,8</sup> The current study showed male predominance which is also observed in different studies.<sup>5,18,19</sup> Diabetes, HTN, and IHD were the most frequent comorbidities reported in this study which are similar to the results of different studies.<sup>14,16,20</sup> High prevalence of diabetes mellitus exists worldwide which leads to an immunosuppressed state which

results in catching different infections.<sup>16</sup> Majority of our patients were nonsmokers (65%); however, a study by Zhang et al.<sup>21</sup> found more prevalence of COVID-19 in the smokers.

Most frequent clinical manifestations of patients in the current study were fever, dry cough, and dyspnea; however; sore throat, fatigue, diarrhea, muscle and joint pains, nasal

**Table 2.** Comparison of patients in ward and ICU during COVID 19 (N = 100).

Variables	In ward (n = 35)	In ICU (n = 65)	p	t	Confidence interval	
	M (SD)	M (SD)			Lower	Upper
SPO2	91.87 (5.76)	89.17 (5.51)	0.003	-3.02	-7.21	-1.80
WBCs	8.51 (4.09)	12.25 (5.14)	0.002	-3.14	-6.11	-1.36
Hb	12.97 (1.09)	12.17 (1.86)	0.005	3.19	0.12	1.59
Neutrophil	67.12 (3.99)	69.12(6.02)	0.81	-0.24	-19.21	15.21
Lymphocytes	23.36 (2.29)	9.14 (1.65)	0.000	4.83	8.30	20.15
Platelets	315,730.76 (4.53)	240,489.36 (3.76)	0.02	2.36	11,529.51	13,895.31
LDH	762.93 (5.78)	1,426.25 (4.56)	0.09	-1.69	-1,445.51	118.86
CRP	10.59 (5.48)	17.76 (3.64)	0.04	-2.12	-12.19	-5.13
Ferritin	678.83 (3.95)	753.66 (4.33)	0.03	-2.27	-309.20	-240.53
Bilirubin	0.90 (.25)	1.02 (.48)	0.51	-0.66	-0.47	0.23
AST	62.92 (1.79)	84.19 (7.04)	0.23	-1.22	-56.18	13.64
ALT	71.64 (3.73)	71.97 (5.83)	0.98	-0.02	-36.25	35.57
Creatinine	1.09 (0.37)	1.25 (0.47)	0.15	-1.46	-0.37	0.06
Urea	46.07 (4.57)	61.19 (3.69)	0.07	-1.84	-31.48	1.26
D-Dimers	40.46 (0.29)	92.97 (0.41)	0.04	-2.11	-375.13	-190.12
Sodium	136.88 (3.93)	137.96 (3.85)	0.26	-1.14	-2.95	0.81
Potassium	3.99 (0.37)	4.19 (0.51)	0.08	-1.75	-0.43	0.02

M = mean, n = total number, SD = standard deviation, SPO2 = pulse oximetry, WBC = white blood cells, Hb = hemoglobin, LDH = lactate dehydrogenase, CRP = C- reactive protein, AST = aspartate aminotransferase, ALT = alanine aminotransferase.

congestion/rhinorrhea, and headache were also encountered but less frequently. These findings are in accordance with other studies.<sup>8,11</sup>

We observed a higher mean leukocyte count as compared to other studies probably because many of our patients had critical illness and admitted in ICU. This is consistent with other studies as higher leukocyte count predicts severe disease.<sup>22,23</sup> Same is true for other inflammatory markers, liver, and renal profile. In the current study, higher mean values were found in the critical patients.

The most common complications in our study group were pneumonia and respiratory failure as this infection most commonly damages the walls and lining of air sacs of the lungs.<sup>24,25</sup> Thirty percent of the patients developed ARDS. AKI is also quite commonly seen in these patients. Our study also strengthens this observation. Despite of near normal values of initial renal function tests, 23% of the patients developed AKI. Therefore, this finding highlights the importance of fluid resuscitation in these patients.<sup>26</sup>

Among the inflammatory markers, significant differences were observed in WBCs, Hb, lymphocytes, platelets, CRP, ferritin, and D-Dimers between patients in ward and ICU which is consistent with the findings reported by Ahmad et al.<sup>27</sup> CRP is an exquisitely sensitive systemic marker of acute-phase response in inflammation, infection, and tissue damage, which could be used as indicator of inflammation.

The present study shows that it is significantly raised in ICU patients. A study by Chen et al.<sup>18</sup> showed contrary results but majority of studies related elevated CRP levels with the disease severity.<sup>27,28</sup> These markers can help in triaging the patients for ICU in our clinical practice. Serum ferritin is also an important inflammatory marker which is significantly high in critical patients.

**Conclusion**

COVID-19 disease has a wide range of symptoms but respiratory system is involved most frequently. Laboratory derangements predict severity in these patients especially the inflammatory markers.

**Limitations of the study**

The data shared is from one clinical center. The number of enrolled patients is small sample considering the expanding prevalence of the disease. We had to exclude the patients with incomplete data as it was a retrospective study.

**List of Abbreviations**

- AKI Acute kidney injury
- ALT Alanine aminotransferase
- ARDS Acute respiratory distress syndrome
- AST Aspartate aminotransferase
- CRP C-reactive protein
- Hb Heamoglobin
- ICU Intensive care unit

LDH Lactate dehydrogenase  
 SpO<sub>2</sub> Oxygen saturation  
 SPSS Statistical Package for the Social Sciences

### Conflict of interest

None to declare.

### Grant support and financial disclosure

None to disclose.

### Ethical approval

The Ethical approval was granted by Ethics Committee/Institutional Review Board/Research Committee, Postgraduate Medical Institute/Ameer ud Din Medical College & Lahore General Hospital, Lahore, Pakistan. (Reference No. 00-125-20 dated 20/07/2020).

### Authors' contributions

**HB and AK:** Conception and design of the study, critical analysis with intellectual input, analysis and interpretation of data.

**SA and AH:** Analysis and interpretation of data.

**KW, MAN, and MJ:** Acquisition of data, drafting the manuscript, conception, and design of the study.

**ALL AUTHORS:** Approved the final version of the manuscript to be published.

### Authors' details

Huma Batool<sup>1</sup>, Asifa Karamat<sup>2</sup>, Khalid Waheed<sup>3</sup>, Sohail Anwar<sup>4</sup>, Syed Arslan Haider<sup>5</sup>, Syed Mazhar Ali Naqvi<sup>6</sup>, Munaza Javed<sup>7</sup>

1. Assistant Professor of Pulmonology, Lahore General Hospital, Lahore, Pakistan
2. Assistant Professor of Pulmonology, Department of Tuberculosis and Chest Medicine, Gulab Devi Hospital, Lahore, Pakistan
3. Professor of Pulmonology & Sleep Medicine, Lahore General Hospital, Lahore, Pakistan
4. Assistant Professor of Pulmonology, University of Lahore Teaching Hospital, Lahore, Pakistan
5. Assistant Professor of Neurology, PINS, Lahore General Hospital, Lahore, Pakistan
6. Associate Professor of Pulmonary and Critical Medicine/MICU, Services Hospital, Lahore, Pakistan
7. Associate Professor of Medicine, Azra Naheed Medical College, Lahore, Pakistan

### References

1. Hiscott J, Alexandridi M, Muscolini M, Tassone E, Palermo E, Soultsioti M, et al. The global impact of the coronavirus pandemic. *Cytokine Growth Factor Rev*. 2020;53(4):1–9. <https://doi.org/10.1016/j.cytogfr.2020.05.010>
2. Casella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). *Treasure Island, FL: StatPearls [Internet]; 2021 [cited 2021 Sep]*. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK554776/>
3. Jamwal A, Bhatnagar S, Sharma P. Coronavirus disease 2019 (COVID-19): current literature and status in India. *Preprints; 2020 [cited 2021 Mar]*. Available from: <https://www.preprints.org/manuscript/202004.0189/v1>
4. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases

from the Chinese center for disease control and prevention. *JAMA*. 2020;323(13):1239–42. <https://doi.org/10.1001/jama.2020.2648>

5. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N Engl J Med*. 2020;382(13):1199–207. <https://doi.org/10.1056/NEJMoa2001316>
6. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis*. 2020;20(4):425–34. [https://doi.org/10.1016/S1473-3099\(20\)30086-4](https://doi.org/10.1016/S1473-3099(20)30086-4)
7. Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chin Med J*. 2020;133(9):1025–31. <https://doi.org/10.1097/CM9.0000000000000744>
8. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA*. 2020;323(11):1061–9. <https://doi.org/10.1001/jama.2020.1585>
9. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *Lancet Respir Med*. 2020;8(4):e21. [https://doi.org/10.1016/S2213-2600\(20\)30116-8](https://doi.org/10.1016/S2213-2600(20)30116-8)
10. Fan BE. Hematologic parameters in patients with COVID-19 infection: a reply. *Am. J Hematol*. 2020;95(8):e213–5. <https://doi.org/10.1002/ajh.25847>
11. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med*. 2020;382(18):1708–20. <https://doi.org/10.1056/NEJMoa2002032>
12. Al Ghamdi M, Alghamdi KM, Ghandoori Y, Alzahrani A, Salah F, Alsulami A, et al. Treatment outcomes for patients with middle eastern respiratory syndrome coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia. *BMC Infect*. 2016;16(1):1–7. <https://doi.org/10.1186/s12879-016-1492-4>
13. Wang JT, Sheng WH, Fang CT, Chen YC, Wang JL, Yu CJ, et al. Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. *Emerg Infect Dis*. 2004;10(5):818–24. <https://doi.org/10.3201/eid1005.030640>
14. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1,591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. *JAMA*. 2020;323(16):1574–81. <https://doi.org/10.1001/jama.2020.5394>
15. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. *JAMA Intern Med*. 2020;180(11):1436–46. <https://doi.org/10.1001/jamainternmed.2020.3596>
16. Asghar MS, Kazmi SJ, Khan NA, Akram M, Khan SA, Rasheed U, et al. Clinical profiles, characteristics, and outcomes of the first 100 admitted COVID-19 patients in Pakistan: a single-center retrospective study in a tertiary care hospital of Karachi. *Cureus*. 2020;12(6):e8712–41. <https://doi.org/10.7759/cureus.c34>
17. Hong KH, Choi JP, Hong SH, Lee J, Kwon JS, Kim SM, et al. Predictors of mortality in middle east respiratory syndrome (MERS). *Thorax*. 2018;73(3):286–9. <https://doi.org/10.1136/thoraxjnl-2016-209313>

18. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507–13. [https://doi.org/10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7)
19. Paudel SS. A meta-analysis of 2019 novel corona virus patient clinical characteristics and comorbidities. Preprints; 2020 [cited 2021 Aug]. Available from: <https://www.researchsquare.com/article/rs-21831/v1> <https://doi.org/10.21203/rs.3.rs-21831/v1>
20. Thomas RL, Halim S, Gurudas S, Sivaprasad S, Owens DR. IDF diabetes Atlas: a review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018. *Diabetes Res Clin Pract*. 2019;157:107840–53. <https://doi.org/10.1016/j.diabres.2019.107840>
21. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*. 2020;75(7):1730–41. <https://doi.org/10.1111/all.14238>
22. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage. *MedRxiv*. Preprints; 2020 [cited 2021 Jul]. Available from: <https://www.medrxiv.org/content/10.1101/2020.02.10.20021584v1>; <https://doi.org/10.1101/2020.02.10.20021584>
23. Omrani-Nava V, Maleki I, Ahmadi A, Moosazadeh M, Hedayatizadeh-Omran A, Roozbeh F, et al. Evaluation of hepatic enzymes changes and association with prognosis in COVID-19 patients. *Hepat Mon*. 2020;20(4):e103179. <https://doi.org/10.5812/hepatmon.103179>
24. Vakili K, Fathi M, Pezeshgi A, Mohamadkhani A, Hajiesmaeili M, Rezaei-Tavirani M, et al. Critical complications of COVID-19: a descriptive meta-analysis study. *Rev Cardiovasc Med*. 2020;21(3):433–42. <https://doi.org/10.31083/j.rcm.2020.03.129>
25. Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. *Chest*. 2020;158(3):1143–63. <https://doi.org/10.1016/j.chest.2020.05.559>
26. Gomes C. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). *Braz J Implantol Health Sci*. 2020;2(3):1.
27. Ahmad Q, DePerrior SE, Dodani S, Edwards JF, Marik PE. Role of inflammatory biomarkers in the prediction of ICU admission and mortality in patients with COVID-19. *Med Res Arch*. 2020;8(12):1–10. <https://doi.org/10.18103/mra.v8i12.2307>
28. Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. *Ann Clin Microbiol Antimicrob*. 2020;19(18):1–7. <https://doi.org/10.1186/s12941-020-00362-2>